Non-ICANS neurologic toxicity after BCMA CAR T: A systematic review and meta-analysis of 4630 multiple myeloma patients

A meta-analysis of data from 4,630 patients with myeloma who were treated with B-cell maturation antigen (BCMA)-directed CAR T-cell therapies evaluated the frequency of non–immune effector cell-associated neurotoxicity syndrome (ICANS) neurologic toxicities. The pooled point estimate for non-ICANS neurologic toxicities was significantly higher for patients who received ciltacabtagene autoleucel compared with those who received idecabtagene vicleucel and other experimental BCMA-directed constructs.